CEA as a blood-based biomarker in anal cancer

Hester, Robert Harrison; Advani, Shailesh; Rashid, Asif; Holliday, Emma B.; Messick, Craig A.; Das, Prajnan; You, Yi Qian Nancy; Taniguchi, Cullen M.; Koay, Eugene J.; Bednarski, Brian Keith; Rodrı́guez-Bigas, Miguel A.; Skibber, John M.; Wolff, Robert A.; Chang, George J.; Minsky, Bruce D.; Foo, Wai Chin; Rothschild, Nicole D.; Morris, Van K.; Eng, Cathy

doi:10.18632/oncotarget.27959

Cited by 7 publications

(3 citation statements)

References 20 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sadeghi et al found that CEA was a useful biomarker in characterizing SCC from basal cell carcinoma [34]. However, one study mentioned that although CEA was increased in anal cancer, but it did not have value in survival prediction, thus it is not a clinical biomarker for SCC [35]. Therefore, CEA is more useful in characterizing AD and SCLC.…”

Section: Discussionmentioning

confidence: 99%

New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?

Li¹,

Zhang²,

Jiang³

et al. 2022

neo

View full text Add to dashboard Cite

The value of serum tumor biomarkers used for lung cancer diagnosis is still controversial in clinical practice. This study aimed to further dissect and evaluate the clinical value of serum progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1) together with a potential new biomarker, the human epididymis protein 4 (HE4) for lung cancer diagnosis, in a large cohort of a Chinese population. Ostensibly healthy individuals, as well as those with benign non-cancerous diseases, benign tumors, lung cancers, and other types of malignancies, were enrolled in the study. Serum ProGRP, NSE, SCC-Ag, CEA, CYFRA21-1, and HE4 were analyzed using the chemiluminescence immunoassay. Data were analyzed utilizing the SPSS and GraphPad Prism software. Detailed dissection of the diagnostic characteristics of serum 6 biomarkers on lung cancer was performed. All 6 biomarkers showed capabilities in characterizing lung cancer from other diseases. ProGRP and NSE were highly specific to small cell lung cancer (SCLC); SCC-Ag was a fair biomarker for NSCLC, specifically SCC histotype; CEA showed specificity to SCLC, followed by NSCLC; CYFRA21-1 was a good biomarker for both SCLC and NSCLC; HE4 showed high specificity to SCLC. For NSCLC characterization, CYFRA21-1+HE4+CEA was the best combinatory pattern in the terms of diagnostic performance (AUC=0.8110). The best combinatory analysis for SCLC was ProGRP+NSE+HE4 (AUC=0.9282). Patients with advanced stage, larger tumor, males, and age 50 or older had higher serum biomarkers levels than those with early stage, smaller tumor, females, and age under 50. Six biomarkers had capabilities in characterizing lung cancer with high or fair diagnostic performance. HE4 is a potential biomarker for both SCLC and NSCLC diagnosis, which merits further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?

Li¹,

Zhang²,

Jiang³

et al. 2022

neo

View full text Add to dashboard Cite

show abstract

“…Based on sequence homology, the CEA gene family can be separated into two subgroups: PSG and CEA ( Streydio et al, 1988 ). CEA has been extensively studied and used as a cancer marker ( Hester et al, 2021 ; Moretto et al, 2021 ; Taheri et al, 2022 ), whereas PSG, especially PSG7, has been relatively poorly studied in the field of oncology, ( Su et al, 2020 ). Unlike other PSGs, PSG7 is characterized by an unblocked N-terminus, which may indicate special biological functions worthy of further research ( Khan and Hammarström, 1990 ).…”

Section: Discussionmentioning

confidence: 99%

PSG7 indicates that age at diagnosis is associated with papillary thyroid carcinoma: A study based on the cancer genome atlas data

2022

View full text Add to dashboard Cite

The age of the patients at diagnosis (age at diagnosis) is a self-contained element of danger for the prognosis of patients with papillary thyroid carcinoma (PTC), which has been well recognized and continuously adopted by the international cancer staging system. However, few studies have investigated its intrinsic mechanisms. In this study, we aim to comprehensively reveal the age-related pathogenesis of PTC and identify potential prognostic biomarkers. We divided the samples into two groups, young and elderly, to filter differentially expressed genes in The Cancer Genome Atlas (TCGA), with an age of 55 years serving as a cutoff. Moreover, we combined univariate, LASSO, and multivariate Cox regression analyses to construct age-related signatures for predicting progression-free survival. Additionally, functional enrichment analysis, immune infiltration analysis, differential expression analysis, clinicopathological correlation analysis, and drug sensitivity analysis were performed in different risk subgroups and expression subgroups. We screened 88 upregulated genes and 58 downregulated genes. Both the LASSO regression model that is validated in TCGA and the model of six age-related prognostic genes (IGF2BP1, GPRC6A, IL37, CRCT1, SEMG1, and PSG7) can be used to evaluate the progression-free survival of PTC patients. The GO, KEGG, and GSEA analyses revealed that each key gene was closely associated with PTC development. Furthermore, CD8+ T cells decreased significantly, while regulatory T cells increased dramatically in the high-risk and PSG7 high expression groups. PSG7 was remarkably correlated with clinicopathological parameters (pathologic stage, T stage, and N stage) of PTC patients, and PSG7 expression was elevated in tumor samples from both TCGA and the Gene Expression Omnibus and was strongly associated with progressive stage and poor prognosis. Our results provide an innovative understanding of the age-related molecular mechanisms of PTC development. PSG7 was identified to exert a critical role in PTC progression and may serve as a promising strategy for predicting the prognosis of PTC.

show abstract

“…However, it is limited by false-positive results in patients with in ammation and non-PCa lesions and false-negative results in Lewis-negative individuals. Likewise, the accuracy of the other blood-based biomarkers is not strong because of their non-speci c aberration in cancers other than PCa [11,12].…”

Section: Introductionmentioning

confidence: 99%

Development of a serum-based miRNA signature for early detection of pancreatic cancer: a multicenter cohort study

Huang,

Gao,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background A grim prognosis of pancreatic cancer (PCa) was attributed to the difficulty in early diagnosis of the disease. Identifying novel biomarkers for early detection of PCa is thus urgent to improve the overall survival rates of patients. Methods The study was performed firstly by identification of candidate microRNAs (miRNAs) in formalin-fixed, paraffin-embedded tissues at either early (n = 100) or advanced (n = 100) stages, to that in benign tissues (n = 100) using microarray profiles, and followed by validation in a serum-based cohort study to assess clinical utility of the candidates as a noninvasive biomarker. In the cohorts, a total of 1273 participants including 571 patients with pancreatic ductal adenocarcinoma, 90 patients with chronic pancreatitis, 217 patients with other pancreatic diseases, and 395 healthy controls from four centers were retrospectively recruited as two cohorts including training and validation cohort. The collected serum specimens were analyzed by real-time polymerase chain reaction. Results We identified 27 miRNAs that were expressed differentially in both early and advanced stages of PCa tissues as compared to the benign. Of which, the top-four was selected by the criteria of log2(fold change) > 4 and FDR < 0.05 as a panel whose diagnostic efficacy was fully assessed in the serum-based cohorts. Patients with PCa at early-stage were significantly discriminated from healthy controls by the panel with AUCs of 0.971 (95%CI: 0.956–0.987) and 0.933 (95%CI: 0.892–0.974) in the training and validation cohorts, respectively. Furthermore, the panel distinguished early-stage PCa from non-PCa including chronic pancreatitis as well as pancreatic cystic neoplasms with AUCs of 0.924 (95%CI: 0.899–0.949) and 0.861 (95%CI: 0.818–0.903) in the training and validation cohorts, respectively. Moreover, the panel eliminated interference from other digestive tumors with a specificity of 90.2%. Strikingly, this panel exhibited superior to four biomarkers routinely used in clinic, including CA19-9, CA125, CEA and CA242. Conclusions A serum-based panel of four miRNAs was developed showing remarkably discriminative ability of early-stage PCa from either healthy controls or other pancreatic diseases, suggesting it may be developed as a novel, noninvasive approach for early screening of PCa in clinic.

show abstract

CEA as a blood-based biomarker in anal cancer

Cited by 7 publications

References 20 publications

New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?

New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?

PSG7 indicates that age at diagnosis is associated with papillary thyroid carcinoma: A study based on the cancer genome atlas data

Development of a serum-based miRNA signature for early detection of pancreatic cancer: a multicenter cohort study

Contact Info

Product

Resources

About